Management of Cirrhotic Edema with Spironolactone

Introduction to Spironolactone Therapy

The American Association for the Study of Liver Diseases recommends that spironolactone is a potassium-sparing diuretic that commonly causes hyperkalemia, occurring in up to 11% of cirrhotic patients on diuretic therapy 1
The European Association for the Study of the Liver states that hyperkalaemia is a significant complication that frequently limits the use of spironolactone in cirrhosis 2, 3

The American College of Gastroenterology suggests that furosemide can be safely increased up to 160 mg/day in cirrhotic patients with edema 2, 3, 6
The European Society of Gastroenterology recommends considering increasing furosemide to 40-80 mg daily while awaiting potassium results, as this addresses significant edema without hyperkalemia risk 5, 6

The American Heart Association advises adding spironolactone 100 mg daily to the furosemide regimen if potassium is normal (3.5-5.0 mmol/L) 5, 4, 6
The National Institute of Diabetes and Digestive and Kidney Diseases recommends checking serum potassium, creatinine, and sodium within 2-3 days of starting spironolactone 5, 1, 6

The American College of Cardiology suggests targeting weight loss: 1 kg/day with peripheral edema present 5, 7, 6
The European Society of Cardiology advises increasing spironolactone by 100 mg increments every 3-5 days up to 400 mg/day if inadequate response 2, 3
The American Association for the Study of Liver Diseases warns to never start spironolactone without knowing baseline potassium in a patient with recent severe hypokalemia—the risk of overcorrection to life-threatening hyperkalemia is substantial 1